Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts [0.03%]
HER2靶向化疗药物ZHER2:V2-培美曲塞的治疗效果及影像学评估研究
Jingya Han,Yan Zhao,Xinming Zhao et al.
Jingya Han et al.
Chemotherapy has always been the first therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) with untreatable oncogenic mutations. However, chemotherapy has demonstrated limited success and is associated with seve...
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors [0.03%]
RO6839921（idalumabulin的聚乙二醇化前药）治疗晚期实体瘤患者的Ⅰ期临床研究
Albiruni R Abdul Razak,Wilson H Miller Jr,Geoffrey L Uy et al.
Albiruni R Abdul Razak et al.
Purpose MDM2 is a negative regulator of the tumor suppressor p53. RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration. On cleavage by plasma esterases, the active principle...
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy [0.03%]
一项关于间断隔日给予5剂量非格司亭与单剂量培非格司亭在乳腺癌患者中对比研究（辅助治疗为多西他赛、阿霉素和环磷酰胺）
Byeong Seok Sohn,Jae Ho Jeong,Jin-Hee Ahn et al.
Byeong Seok Sohn et al.
Aim To compare the efficacy and safety of intermittent every other days 5-dose filgrastim with single pegfilgrastim in patients with breast cancer receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. Methods I...
Randomized Controlled Trial
Investigational new drugs. 2020 Jun;38(3):866-873. DOI:10.1007/s10637-019-00863-8
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants [0.03%]
伏立康唑对 Lorlatinib 药代动力学的影响：健康志愿者中的 I 期开放标记交叉研究结果
Maulik Patel,Joseph Chen,Stephanie McGrory et al.
Maulik Patel et al.
Background The third-generation tyrosine kinase inhibitor lorlatinib is approved for the treatment of ALK-positive metastatic NSCLC. CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted t...
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer [0.03%]
一项I期剂量递增研究：在晚期或转移性癌症患者中，同时使用检查点激酶1（CHK1）抑制剂prexasertib与p38丝裂原活化蛋白激酶（p38 MAPK）抑制剂ralimetinib的效果
Johanna C Bendell,Helge G Bischoff,Jimmy Hwang et al.
Johanna C Bendell et al.
Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which may be safely admin...
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study [0.03%]
伏司妥替尼（mTORC1/2双靶点抑制剂）治疗复发胶质母细胞瘤的I期临床研究：CCTG研究
Sarah Lapointe,Warren Mason,Mary MacNeil et al.
Sarah Lapointe et al.
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to sensitize cultured glioma c...
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment [0.03%]
直接抗病毒药物对治愈肝细胞癌后丙型肝炎病毒相关的影响
Yuan-Hung Kuo,Jing-Houng Wang,Kuo-Chin Chang et al.
Yuan-Hung Kuo et al.
This study was done to elucidate the influence of direct-acting antiviral (DAA) agents on the recurrence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related HCC (HCV-HCC) after curative therapies. HCV-HCC pati...
Kevin W Wellington,Vincent Hlatshwayo,Natasha I Kolesnikova et al.
Kevin W Wellington et al.
In a previous study we reported on the synthesis of 1,4-naphthoquinone-sulfides by thiolation of 1,4-naphthohydroquinones with primary aryl and alkyl thiols using laccase as catalyst. These compounds were synthesized as Vitamin K3 analogues...
Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial [0.03%]
儿茶素漱口水可保护头颈部肿瘤放疗患者的口腔黏膜：一项前瞻性非随机Ⅰ期临床试验
Wanqi Zhu,Hui Mei,Li Jia et al.
Wanqi Zhu et al.
Radiation-induced oral mucositis has a dismal outcome with limited treatment options. We conducted a phase I study to evaluate the safety and preliminary efficacy of epigallocatechin-3-gallate (EGCG) mouthwash when given along with radiatio...
7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells [0.03%]
7-氯喹啉-1,2,3-三氮唑甲酰胺氨诱导人类膀胱癌细胞周期阻滞和凋亡
Mariana S Sonego,Natália V Segatto,Lucas Damé et al.
Mariana S Sonego et al.
In the present study, the antitumoral properties of a series of 7-chloroquinoline-1,2,3-triazoyl-carboxamides (QTCA) were investigated by analyzing their cytotoxic activities against human bladder cells (5637; grade II carcinoma). In additi...